Abstract
Optimization of a 5-oxopyrrolopyridine series based upon structure-activity relationships (SARs) developed from our previous efforts on a number of related bicyclic series yielded compound 2s (BMS-767778) with an overall activity, selectivity, efficacy, PK, and developability profile suitable for progression into the clinic. SAR in the series and characterization of 2s are described.
MeSH terms
-
Acetamides / chemical synthesis
-
Acetamides / chemistry*
-
Acetamides / pharmacology*
-
Animals
-
Bridged Bicyclo Compounds, Heterocyclic / chemical synthesis
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry*
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Catalytic Domain
-
Dipeptidyl Peptidase 4 / chemistry
-
Dipeptidyl Peptidase 4 / metabolism*
-
Dipeptidyl-Peptidase IV Inhibitors / chemical synthesis
-
Dipeptidyl-Peptidase IV Inhibitors / chemistry*
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacology*
-
Drug Design*
-
Glucose Tolerance Test
-
Humans
-
Male
-
Mice
-
Models, Molecular
-
Pyrroles / chemical synthesis
-
Pyrroles / chemistry*
-
Pyrroles / pharmacology*
-
Substrate Specificity
Substances
-
2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo(3,4-b)pyridin-6(7H)-yl)-N,N-dimethylacetamide
-
Acetamides
-
Bridged Bicyclo Compounds, Heterocyclic
-
Dipeptidyl-Peptidase IV Inhibitors
-
Pyrroles
-
Dipeptidyl Peptidase 4